Another round of disappointing data for NGD 2000-1 caused Neurogen Corp.'s stock to drop nearly 19 percent Wednesday, and made further development of the product in rheumatoid arthritis an unlikely plan. (BioWorld Today)

CollaGenex Starts Periostat Pivotal Program In Rosacea

June 16, 2004

By Karen Carey

QLT, Atrix Merging In $855M Deal To Grow Pipeline, Build Business

June 15, 2004

By Karen Carey

In a transaction valued at $855 million, QLT Inc. and Atrix Laboratories Inc. are merging into a single entity with two marketed products and a multitude of pipeline possibilities. (BioWorld Today)

Nabi Begins Phase IV Trial To Expand Potential For PhosLo

June 14, 2004

By Karen Carey

Isolagen Offering Raises $59.5M For Autologous Cellular Therapies

June 11, 2004

By Karen Carey

Tissue-regeneration company Isolagen Inc. brought in $59.5 million in a follow-on offering Thursday, leaving it with wrinkle-free plans to begin pivotal trials and bring its lead anti-aging product to the market. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...